Inhibikase Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Income Taxes (Table)

12 Months Ended

Dec. 31, 2025

The reconciliation of the U.S. federal statutory rate to the Company’s effective tax rate is as follows:


			Year Ended December 31,					Year Ended December 31,
			2025					2024
			Amount			Percent		Amount			Percent

Pretax Income (Loss)		$		(48,259	)		$		(27,520	)

US Federal Statutory Tax Rate				(10,134	)	21.0%			(5,779	)	21.0%
Tax Credits:
	R&D tax credits			—		0.0%			(712	)	2.6%
	Limitation on tax attributes			—		0.0%			1,806		-6.6%
Change in valuation allowance				7,142		-14.8%			4,023		-14.6%
Nontaxable or Nondeductible Items:
	Stock-based compensation			1,726		-3.6%			666		-2.4%
	Acquisition costs			1,550		-3.2%			—		0.0%
	Other			(284	)	0.6%			(4	)	0.0%

Total		$		—		0.0%	$		—		0.0%

The significant components of the Company’s deferred tax assets (liabilities) consist of the following at December 31, 2025 and 2024:


	Year Ended December 31,
	December 31,
	2025			2024
Deferred tax assets:
Net operating loss carryforwards	$	14,981,661		$	12,320,874
Capitalized research and development		10,495,043			6,895,747
Stock-based compensation		5,413,025			3,780,237
Accrued expenses		767,486			218,802
Fixed assets		—			447
Other		1,626			1,728
Total deferred tax assets before valuation allowance		31,658,841			23,217,835
Deferred tax asset valuation allowance		(31,658,841	)		(23,217,835	)
Net deferred tax asset (liability)	$	—		$	—